ClinicalTrials.gg
CompletedNCT06700499Updated Mar 17, 2026

A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of AK120 300mg Q2W (JAK inhibitor users need to double the initial dose) in Atopic Dermatitis, sponsored by Akeso. Completed at 50 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jul 2024, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
450
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Enrollment
35th of 190
450 · median 164
Started
2024
with 36 others
Phase 2
58 of 206
16 open now
Registered
130th of 206
by date
Lead sponsor
6 of 206
Akeso

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 35th largest by enrollment of the 190 interventional ones that give a count, is one of 37 that started in 2024, is one of 58 in phase 2, and was the 130th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, open label phase II clinical study to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate to severe atopic dermatitis.

Read the detailed description

This is a multicenter, open label phase II clinical study to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate to severe atopic dermatitis. The total duration of the study (including screening period, treatment period and follow-up period) planned for each subject is approximately 25 weeks.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged ≥18≤75 years old.
  2. Atopic dermatitis (AD) diagnosed at least half a year before screening.
  3. Subject with EASI score ≥16, IGA ≥ 3, BSA ≥ 10% at screening and baseline.
  4. Subjects who are suitable for continue using biological treatment assessed by investigator

Exclusion criteria

Exclusion Criteria:

  1. Acute onset of AD within 4 weeks before drug administration.
  2. The accompany disease have been assessed by the investigators during screening period as unsuitable for participation in this study.
  3. Any history or symptoms of malignant tumors in any organ within 5 years prior to screening, regardless of whether treatment has been received and whether there are signs of recurrence or
  4. Have a known or suspected history of diseases, including a history of invasive infections.
  5. Having undergone or planned major surgery within 4 weeks prior to drug administration, or unable to fully recover from surgery prior to drug administration.
  6. any medical or psychological condition that puts subjects at risk or may affect the study results assessed by investigators.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
450 participants (actual)

Study arms

  • Experimental
    AK120 300mg Q2W(Double the initial dose)

    AK120 600mg (first day) then 300mg Q2W SC until week 14.

    Drug: AK120 300mg Q2W (JAK inhibitor users need to double the initial dose)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent adverse events (TEAEs)

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment

    Time frame: through study completion, an average of 25 weeks

Secondary outcomes

  1. Eczema Area and Severity Index (EASI) score

    Percentage change in EASI score from baseline. EASI score is to assesses the extent and severity of eczema in four body regions with the score ranges from 0 to 72. The higher the score, the more severe the eczema.

    Time frame: baseline to week 20

  2. Investigator's Global Assessment (IGA) 0/1

    Percentage of subjects who achieved 0/1 in the IGA. The IGA is an assessment instrument used in clinical studies to rate the severity of atopic dermatitis globally, based on a 5-point scale ranging from 0 (clear) to 4 (severe).

    Time frame: from baseline to week 20

  3. Affected body surface area (BSA) score

    Percentage change in BSA score from baseline. Body surface area affected by atopic dermatitis will be assessed for each section of the body (0-100%) and will be reported as a percentage of all major body sections combined.

    Time frame: from baseline to week 20

  4. Area under the curve(AUC) of AK120

    Assessment of AUC of AK120.

    Time frame: before drug administration at week 0/4/8/12/16

  5. Anti-drug antibodies (ADA) of AK120

    Percentage of subjects with detectable anti drug antibodies (ADA) of AK120.

    Time frame: before drug administration at week 0/4/8/16/20

07

Study locations

50 sites
  • Beijing Luhe Hospital Affiliated to Capital Medical University
    Beijing, Beijing Municipality, China
  • Peking University Third Hospital
    Beijing, Beijing Municipality, China
  • Xiyuan Hospital of CACMS
    Beijing, Beijing Municipality, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian, China
  • The Second Affiliated Hospital of Xiamen Medical College
    Xiamen, Fujian, China
  • The Second Hospital & Clinical Medical School, Lanzhou University
    Lanzhou, Gansu, China
  • Guangdong Provincial Dermatology Hospital
    Guangzhou, Guangdong, China
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong, China
  • Second people's Hospital of Shenzhen
    Shenzhen, Guangdong, China
  • Shenzhen Hospital of University of Hong Kong
    Shenzhen, Guangdong, China
  • Liuzhou People's Hospital
    Liuzhou, Guangxi, China
  • Cangzhou People's Hospital
    Cangzhou, Hebei, China
  • Affiliated Hospital of Chengde Medical University
    Chengde, Hebei, China
  • Shijiazhuang Hospital of Traditional Chinese Medicine
    Shijiazhuang, Hebei, China
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • People Hospital of Xingtai
    Xingtai, Hebei, China
  • The Second Affiliated Hospital of Xingtai Medical College
    Xingtai, Hebei, China
  • Anyang District Hospital
    Anyang, Henan, China
  • The Second Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan, China
  • Sanmenxia Central Hospital
    Sanmenxia, Henan, China
  • Jingzhou Central Hospital
    Jingzhou, Hubei, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei, China
  • Wuhan No.1 Hospital
    Wuhan, Hubei, China
  • Changde First People's Hospital
    Changde, Hunan, China
  • XiangYa Hospital CentralSouth University
    Changsha, Hunan, China
  • Yueyang Central Hospital
    Yueyang, Hunan, China
  • The Affiliated Hospital of Inner Mongolia Medical College
    Hohhot, Inner Mongolia, China
  • Affiliated Hospital of Nantong University
    Nantong, Jiangsu, China
  • Wuxi People's Hospital
    Wuxi, Jiangsu, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu, China
  • The Affiliated Hospital of Yanbian University Yanbian Hospital
    Yanbian, Jilin, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
  • Shandong First Medical University Affiliated Dermatology Hospital
    Jinan, Shandong, China
  • Yantai Yuhuangding Hospital
    Yantai, Shandong, China
  • Shanghai Skin Disease Hospital
    Shanghai, Shanghai Municipality, China
  • Shanghai Yueyang Integrated Traditional Chinese Medicine and Western Medicine Hospital
    Shanghai, Shanghai Municipality, China
  • Taiyuan Central Hospital
    Taiyuan, Shanxi, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan, China
  • The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
    Tianjin, Tianjin Municipality, China
  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
    Tianjin, Tianjin Municipality, China
  • Xinjiang Uygur Municipal People's Hospital
    Ürümqi, Xinjiang, China
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
  • Qujing No.1 Hospital
    Qujing, Yunnan, China
  • Affiliated Hangzhou First People's Hospital
    Hangzhou, Zhejiang, China
  • Hangzhou Third People's Hospital
    Hangzhou, Zhejiang, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Jiaxing Second Hospital
    Jiaxing, Zhejiang, China
  • The First Hospital of Jiaxing
    Jiaxing, Zhejiang, China
  • Ningbo No.2 Hospital
    Ningbo, Zhejiang, China
  • Taizhou Central Hospital
    Taizhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Jul 2025, 12 months.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 12 months is close to that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2024
First posted
Nov 22, 2024
StartActual
Jul 8, 2024
Primary completionActual
Jul 31, 2025
CompletionActual
Sep 11, 2025
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06700499
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Nov 22, 2024
Start date
Jul 8, 2024
Primary completion
Jul 31, 2025
Completion
Sep 11, 2025
Last update
Mar 17, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AK120

Start the discussion